Acrivon Therapeutics (NASDAQ:ACRV) Rating Lowered to Neutral at LADENBURG THALM/SH SH

Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by equities research analysts at LADENBURG THALM/SH SH from a “buy” rating to a “neutral” rating in a research note issued on Monday, MarketBeat reports.

Other research analysts have also issued reports about the stock. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Acrivon Therapeutics in a research report on Thursday, April 25th. BMO Capital Markets boosted their target price on Acrivon Therapeutics from $18.00 to $25.00 and gave the stock an “outperform” rating in a research report on Friday, April 26th. JMP Securities raised their price target on Acrivon Therapeutics from $14.00 to $17.00 and gave the company a “market outperform” rating in a report on Thursday, April 25th. Finally, Piper Sandler boosted their price objective on Acrivon Therapeutics from $26.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Acrivon Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $22.63.

Acrivon Therapeutics Stock Down 9.1 %

Shares of NASDAQ ACRV opened at $9.09 on Monday. The company has a market cap of $205.80 million, a P/E ratio of -3.33 and a beta of 1.93. Acrivon Therapeutics has a 52 week low of $3.19 and a 52 week high of $14.30. The business has a 50-day simple moving average of $6.77 and a two-hundred day simple moving average of $5.37.

Acrivon Therapeutics (NASDAQ:ACRV) last released its quarterly earnings data on Thursday, March 28th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.14). Equities research analysts anticipate that Acrivon Therapeutics will post -3.16 EPS for the current year.

Insider Buying and Selling

In other Acrivon Therapeutics news, major shareholder Perceptive Advisors Llc purchased 2,353,000 shares of Acrivon Therapeutics stock in a transaction on Thursday, April 11th. The shares were acquired at an average cost of $8.50 per share, for a total transaction of $20,000,500.00. Following the completion of the transaction, the insider now directly owns 5,360,858 shares of the company’s stock, valued at $45,567,293. The purchase was disclosed in a filing with the SEC, which is available at this link. 7.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Acrivon Therapeutics stock. Exchange Traded Concepts LLC raised its position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) by 34.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,289 shares of the company’s stock after acquiring an additional 3,370 shares during the quarter. Exchange Traded Concepts LLC owned approximately 0.06% of Acrivon Therapeutics worth $65,000 at the end of the most recent quarter. Institutional investors own 71.62% of the company’s stock.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.